Macrocyclic inhibitors of flaviviridae viruses

1. A method for treating a viral infection caused by a Hepatitis C virus in a human patient comprising administering to the human patient in need thereof a therapeutically effective amount of a compound of Formula I:

or a pharmaceutically acceptable salt or a pharmaceutical composition thereof,

wherein:

X 1 is O, S, or NR 1 ;

each R 1 is independently H, optionally substituted (C 1 -C 4 )alkyl, optionally substituted (C 2 -C 4 )alkenyl or optionally substituted (C 2 -C 4 )alkynyl;

each R 2 or R 3 is independently H, optionally substituted (C 1 -C 4 )alkyl, optionally substituted (C 2 -C 4 )alkenyl, optionally substituted (C 2 -C 4 )alkynyl, halogen, cyano, C(O)R 1 , C(O)OR 1 or CON(R 1 ) 2 ; or R 2 and R 3 when taken together with the carbon to which they are both attached form —C(═O)—, —C(═S)— or —C(═NR 1 )—;

A is O, S(O) n , NR 4 or optionally substituted (C 1 -C 2 )alkylene;

each n is independently 0, 1 or 2;

each R 4 is independently H, optionally substituted (C 1 -C 4 )alkyl, optionally substituted (C 2 -C 4 )alkenyl, optionally substituted (C 2 -C 4 )alkynyl, cyano, C(O)R 7 , C(O)OR 7 , CON(R 7 ) 2 , S(O)R 16 , S(O) 2 R 16 , S(O) 2 OR 7 or S(O) 2 N(R 7 ) 2 ;

R 5 is optionally substituted aryl(C 0 -C 4 )alkyl, optionally substituted heterocyclyl(C 0 -C 4 )alkyl, optionally substituted cycloalkyl(C 0 -C 4 )alkyl or optionally substituted (C 1 -C 8 )alkyl wherein each optionally substituted aryl(C 0 -C 4 )alkyl, optionally substituted cycloalkyl(C 0 -C 4 )alkyl or optionally substituted (C 1 -C 8 )alkyl is optionally substituted with one or more R 6 ;

each R 6 is independently halo, CF 3 , OR 4 , CH 2 OR 4 , SR 4 , S(O)R 16 , S(O) 2 R 16 , N(R 1 ) 2 , NHCOR 1 , NHC(O)OR 1 , NHC(O)N(R 1 ) 2 , NHC(NR 1 )R 1 , NHC(NR 1 )R 1 , NHC(NR 1 )N(R 1 ) 2 , C(O)R 1 , C(O)N(R 1 ) 2 , CO 2 R 1 , S(O) 2 OR 1 , S(O) 2 N(R 1 ) 2 , NHS(O) 2 OR 1 , NHS(O) 2 R 16 , NHS(O) 2 N(R 1 ) 2 , P(O)(OR 1 ) 2 , P(O)(OR 1 )(N(R 1 ) 2 ), P(O)(R 7 )(OR 1 ), OP(O)(OR 1 ) 2 , OP(O)(OR 1 )(N(R 1 ) 2 ), NHP(O)(OR 1 ) 2 or NHP(O)(OR 1 )(N(R 1 ) 2 );

each R 7 is H, optionally substituted (C 1 -C 8 )alkyl, optionally substituted (C 2 -C 8 )alkenyl, optionally substituted (C 2 -C 8 )alkynyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted cycloalkyl, optionally substituted aryl(C 1 -C 4 )alkyl, optionally substituted cycloalkyl(C 1 -C 4 )alkyl or optionally substituted heterocyclyl(C 1 -C 4 )alkyl;

each R 16 is optionally substituted (C 1 -C 8 )alkyl, optionally substituted (C 2 -C 8 )alkenyl, optionally substituted (C 2 -C 8 )alkynyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted cycloalkyl, optionally substituted aryl(C 1 -C 4 )alkyl, optionally substituted cycloalkyl(C 1 -C 4 )alkyl or optionally substituted heterocyclyl(C 1 -C 4 )alkyl;

each R 8 , R 8b , R 9 or R 9b is independently H, optionally substituted (C 1 -C 8 )alkyl, optionally substituted (C 2 -C 8 )alkenyl, optionally substituted (C 2 -C 8 )alkynyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted cycloalkyl, optionally substituted aryl(C 1 -C 4 )alkyl, optionally substituted cycloalkyl(C 1 -C 4 )alkyl, optionally substituted heterocyclyl(C 1 -C 4 )alkyl, OR 4 , SR 4 , S(O)R 16 , S(O) 2 R 16 or N(R 4 ) 2 ;

provided that each R 8 , R 8b , R 9 and R 9b is not H; and

provided that when R 9 is OH and both R 8b and R 9b are H, then R 8 is not

A 1 is optionally substituted (C 1 -C 5 )alkylene, optionally substituted (C 2 -C 5 )alkenylene or optionally substituted (C 2 -C 5 )alkynylene, wherein a sp 3 carbon atom of said optionally substituted (C 2 -C 5 )alkylene, optionally substituted (C 2 -C 5 )alkenylene, or optionally substituted (C 2 -C 5 )alkynylene, is optionally replaced by O, S(O) n or NR 4 , and A 2 is optionally substituted arylene, optionally substituted heteroarylene, optionally substituted heterocyclene or optionally substituted cycloalkylene, or

A 1 is optionally substituted aryl(C 0 -C 2 )alkylene, optionally substituted cycloalkyl(C 0 -C 2 )alkylene or optionally substituted heterocyclyl(C 0 -C 2 )alkylene, wherein a sp 3 carbon atom of said optionally substituted aryl(C 0 -C 2 )alkylene, optionally substituted cycloalkyl(C 0 -C 2 )alkylene or optionally substituted heterocyclyl(C 0 -C 2 )alkylene is optionally replaced by O, S(O) n or NR 4 , and A 2 is optionally substituted (C 1 -C 3 )alkylene, optionally substituted (C 2 -C 3 )alkenylene or optionally substituted (C 2 -C 3 )alkynylene;

R 12 is H, optionally substituted (C 1 -C 4 )alkyl, optionally substituted (C 2 -C 4 )alkenyl or optionally substituted (C 2 -C 4 )alkynyl;

each R a is independently H, (C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl, (C 2 -C 8 )alkynyl, aryl, heterocyclyl, aryl(C 1 -C 8 )alkyl, cycloalkyl or cycloalkyl(C 1 -C 8 )alkyl and

wherein when R 1 , R 2 , R 3 , R 4 , R 7 , R 8 , R 9 , R 8b , R 9b , R 12 , R 16 , A, A 1 or A 2 is substituted, the substitutent is, independently, one or more substituents selected from the group consisting of halo, CN, CF 3 , N 3 , N(R a ) 2 , SR a , OR a , R a , NHCOR a , NHC(O)OR a , NHC(O)N(R a ) 2 , NHC(NR a )R a , NHC(NR a )N(R a ) 2 , C(O)R a , C(O)N(R a ) 2 , CO 2 R a , S(O) 2 OR a , S(O) 2 N(R a ) 2 , NHS(O) 2 OR a , NHS(O) 2 N(R a ) 2 , OP(O)(OR a ) 2 , OP(O)(OR a )(N(R a ) 2 ), NHP(O)(OR a ) 2 and NHP(O)(OR a )(N(R a ) 2 ).

2. The method of claim 1 further comprising administering at least one additional therapeutic agent selected from the group consisting of interferons, ribavirin or its analogs, HCV NS3 protease inhibitors, HCV NS5a inhibitors, nucleoside or nucleotide inhibitors of HCV NS5B polymerase, non-nucleoside inhibitors of HCV NS5B polymerase, and TLR-7 agonists; or mixtures thereof.

3. A method for treating a viral infection caused by a Hepatitis C virus in a human patient comprising administering to the human patient in need thereof a therapeutically effective amount of a compound selected from the group consisting of

or a pharmaceutically acceptable salt or a pharmaceutical composition thereof.

4. The method of claim 3 further comprising administering at least one additional therapeutic agent selected from the group consisting of interferons, ribavirin or its analogs, HCV NS3 protease inhibitors, HCV NS5a inhibitors, nucleoside or nucleotide inhibitors of HCV NS5B polymerase, non-nucleoside inhibitors of HCV NS5B polymerase, and TLR-7 agonists; or mixtures thereof.